GeneDx Holdings (NASDAQ: WGS) reported Q4 EPS of ($0.61), $0.70 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $121 million versus the consensus estimate of $120.55 million.

GUIDANCE:

GeneDx Holdings sees FY2026 revenue of $540-555 million, versus the consensus of $543 million.

For earnings history and earnings-related data on GeneDx Holdings (WGS) click here.